Stay updated on Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page.

Latest updates to the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page
- Check4 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check18 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations across various countries, as well as updates to drug-related topics and terms. Notably, the content related to Trastuzumab Emtansine and Atezolizumab has been revised.SummaryDifference5%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page has updated its version from v2.16.11 to v2.16.12, indicating a revision in the content. Additionally, the previous estimated timestamps for 'Results First Posted' and 'Last Update Posted' have been removed.SummaryDifference0.1%
- Check39 days agoChange DetectedThe study has expanded to include 51 locations and the results have been posted as of August 8, 2025. However, several key outcome measures related to the study have been removed due to the sponsor's decision to prematurely terminate the study.SummaryDifference80%
- Check46 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page.